Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial

Ann Neurol. 1978 Jun;3(6):502-4. doi: 10.1002/ana.410030607.

Abstract

A double-blind clinical trial of tranexamic acid was carried out on 39 patients with fresh subarachnoid hemorrhage from a ruptured aneurysm. Twenty patients received tranexamic acid, 6 gm daily for 14 to 21 days, while 19 patients received conventional therapy of bedrest and dexamethasone when cerebral edema developed, plus isotonic saline. Rebleeding and mortality were reduced by one-fourth and one-fifth, respectively (p less than 0.001). No side-effects were observed. Tranexamic acid is valuable in the treatment of subarachnoid hemorrhage caused by ruptured intracranial aneurysms.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aminocaproic Acid / therapeutic use
  • Clinical Trials as Topic
  • Cyclohexanecarboxylic Acids / therapeutic use*
  • Double-Blind Method
  • Female
  • Humans
  • Intracranial Aneurysm / complications*
  • Male
  • Middle Aged
  • Rupture, Spontaneous
  • Subarachnoid Hemorrhage / drug therapy*
  • Subarachnoid Hemorrhage / etiology
  • Tranexamic Acid / therapeutic use*

Substances

  • Cyclohexanecarboxylic Acids
  • Tranexamic Acid
  • Aminocaproic Acid